Cytokinetics (CYTK) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Cytokinetics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
Yahoo FinanceMar 1 09:15 ET
A Quick Look at Today's Ratings for Cytokinetics(CYTK.US), With a Forecast Between $78 to $107
Moomoo NewsMar 1 08:00 ET · Ratings
Cytokinetics' Earnings Call: Progress Amid Challenges
TipRanksFeb 28 19:18 ET
Express News | Cytokinetics Shares Are Trading Lower After the Company Reported a Q4 Gaap EPS Miss
BenzingaFeb 28 12:47 ET
Cytokinetics Q4 Loss Wider Than Expected, Aficamten in Focus
Zacks Feb 28 12:30 ET
Stifel Nicolaus Remains a Buy on Cytokinetics (CYTK)
TipRanksFeb 28 08:47 ET · Ratings

Comments

Narga101

Feb 20 17:35

hidden gem right here

$Cytokinetics (CYTK.US)$

1

Movers and Shakers

Dec 24, 2024 07:57

Columns Today's Pre-Market Movers and Top Ratings | TIVC, NEUE, X, and More

Morning Movers
Gapping up
$Tivic Health Systems (TIVC.US)$ shares jumped 76% in Tuesday premarket after CEO Jennifer Ernst announced plans for 2025 cash flow initiatives and disease-specific clinical trials for regulatory approvals.
$NeueHealth (NEUE.US)$ stock surged 62% after announcing its agreement to be acquired and taken private by a New Enterprise Associates affiliate in a deal valued at approximately $1.3 billion.
$SEALSQ Corp (LAES.US)$ shares c...

18

4

Sean Parker

Nov 19, 2024 02:56

$Cytokinetics (CYTK.US)$
Cytokinetics (CYTK) and Bayer have established an exclusive licensing agreement for aficamten in Japan, focusing on treating hypertrophic cardiomyopathy (HCM). The deal includes an upfront payment of €50 million to Cytokinetics, with potential additional earnings of €90 million in milestones through commercial launch (including €20 million near-term) and up to €490 million in commercial milestone payments. The collaboration involves tiered royalties on Japanese sales and ...

Mr Long Term

Aug 13, 2024 17:42

Columns Top Calls on Wall Street: Starbucks, Dell, Warner Bros. and More.

Top 5 Upgrades:
Baird upgraded Starbucks $Starbucks (SBUX.US)$ to Outperform from Neutral with a price target of $110, up from $81. The firm sees a more favorable risk/reward on Starbucks shares following the hiring of Brian Niccol as CEO.
Barclays upgraded Dell Technologies $Dell Technologies (DELL.US)$ to Equal Weight from Underweight with an unchanged price target of $97. The firm says much of the artificial intelligence "hype" ...

12

2

Rocketier (MAXN)

Jun 11, 2024 07:25

$Cytokinetics (CYTK.US)$ cmonnn I know u can up alot further! 🚀

CYTK Cytokinetics

Trade Overview

Capital Trend

News

Comments

Trending Stocks